Psyence Biomedical Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PBM research report →
Price Chart
About the company
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care.
- CEO
- Jody Aufrichtig
- IPO
- 2021
- Employees
- 12
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on PBM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $95.47K
- P/E
- -0.40
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.16
- EV/EBITDA
- 1.06
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -58.62%
- ROIC
- -36.81%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-5,266-23.4%
- Op Income
- $-6,237,511
- Net Income
- $-6,936,421-785.6%
- EPS
- $-12.56-805.6%
- OCF Growth
- -118.1%
- FCF Growth
- -130.8%
- 52W High
- $175.78
- 52W Low
- $1.92
- 50D MA
- $4.54
- 200D MA
- $7.13
- Beta
- 1.69
- RSI (14)
- 45
- Avg Volume
- 93.73K
No earnings-call transcripts are available for PBM yet.
- Free Float
- 100.0%
- Shares Outstanding
- 19.02K
- Float Shares
- 19.02K
of shares held by institutions
2 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Parallel Advisors, LLC | 151.25K | 0 |
| Advisorshares Investments LLC | 122.18K | ▲ 122.18K |
| Morgan Stanley | 37.80K | ▲ 37.80K |
| Jane Street Group, LLC | 30.43K | ▲ 30.43K |
| Xtx Topco Ltd | 15.09K | ▲ 15.09K |
| Citadel Advisors LLC | 11.69K | ▲ 11.69K |
| Stonehage Fleming Financial Services Holdings Ltd | 89 | 0 |
| Ubs Group AG | 60 | ▲ 60 |
| Caitlin John, LLC | 35 | ▲ 35 |
Held by 1 ETFs
Biggest fund positions in PBM by dollar value.
Our PBM coverage
Recent articles, reports, and earnings notes.
No research on PBM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PBM report →Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
globenewswire.com · Oct 5
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
globenewswire.com · Sep 28
Psyence BioMed Announces Strategic Ibogaine Investment
globenewswire.com · Sep 23
Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
globenewswire.com · Sep 14
Modular Medical Secures National PBM Contract For Pivot Insulin Pump
benzinga.com · Sep 4
Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development
globenewswire.com · Aug 18
Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform
businesswire.com · Jun 16
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
globenewswire.com · May 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.